Charles Schwab
ONCT

Charles Schwab’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Charles Schwab’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-1,612
Closed -$17.3K – 3566
2023
Q4 		$17.3K Hold
1,612
– – ﹤0.01% 3497
2023
Q3 		$9.78K Hold
1,612
– – ﹤0.01% 3565
2023
Q2 		$11.1K Hold
1,612
– – ﹤0.01% 3592
2023
Q1 		$25.3K Hold
1,612
– – ﹤0.01% 3479
2022
Q4 		$32.2K Hold
1,612
– – ﹤0.01% 3444
2022
Q3 		$29K Hold
1,612
– – ﹤0.01% 3445
2022
Q2 		$36K Sell
1,612
-3,079
-66% -$68.7K ﹤0.01% 3441
2022
Q1 		$131K Sell
4,691
-793
-14% -$28.9K ﹤0.01% 3374
2021
Q4 		$249K Hold
5,484
– – ﹤0.01% 3326
2021
Q3 		$458K Hold
5,484
– – ﹤0.01% 3174
2021
Q2 		$521K Buy
5,484
+4,691
+592% +$557K ﹤0.01% 3160
2021
Q1 		$132K Buy
+793
New +$105K ﹤0.01% 3359
2019
Q2 		– Sell
-75
Closed -$13K – 3277
2019
Q1 		$13K Hold
75
– – ﹤0.01% 3190
2018
Q4 		$9K Sell
75
-23
-23% -$4.6K ﹤0.01% 3145
2018
Q3 		$22K Buy
+98
New +$235K ﹤0.01% 3131
2016
Q3 		– Sell
-11
Closed -$9K – 3051
2016
Q2 		$9K Hold
11
– – ﹤0.01% 3099
2016
Q1 		$8K Hold
11
– – ﹤0.01% 3056
2015
Q4 		$12K Hold
11
– – ﹤0.01% 3094
2015
Q3 		$13K Hold
11
– – ﹤0.01% 3087
2015
Q2 		$24K Hold
11
– – ﹤0.01% 3083
2015
Q1 		$11K Hold
11
– – ﹤0.01% 3079
2014
Q4 		$12K Hold
11
– – ﹤0.01% 3104
2014
Q3 		$12K Hold
11
– – ﹤0.01% 3070
2014
Q2 		$22K Sell
11
-85
-89% -$168K ﹤0.01% 3082
2014
Q1 		$206K Hold
96
– – ﹤0.01% 2936
2013
Q4 		$222K Buy
96
+56
+140% +$128K ﹤0.01% 2927
2013
Q3 		$106K Sell
40
-12
-23% -$59.7K ﹤0.01% 3029
2013
Q2 		$479K Buy
+52
New +$401K ﹤0.01% 2543

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
QPW
Quantum Private Wealth Tampa, Florida $390M AUM 58.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Charles Schwab's ONCT Position: Q1 2024 in Review

Charles Schwab sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2024, closing a stake of 1,612 shares — an estimated $17.3K sold.

Charles Schwab first reported a position in ONCT in Q2 2013 and held it in 28 quarters. The position peaked at $521K in Q2 2021. 24 funds tracked by Wall St. Rank hold ONCT as of Q1 2024.

  • Charles Schwab reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Charles Schwab sold 1,612 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $17.3K.
  • Charles Schwab first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 28 quarters.
  • Charles Schwab's Oncternal Therapeutics, Inc. Common Stock position peaked at $521K in Q2 2021.
  • 24 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Charles Schwab's 13F filing for Q1 2024, filed 9 May 2024.